Benitec Biopharma Inc. · NASDAQ:BNTC
Benitec Biopharma — Shareholder Meeting (November 2018)
17 slides from Benitec Biopharma's shareholder meeting presentation, Nov 8, 2018
Slide 1: Pathway to Value Creation
PATHWAY TO VALUE CREATION NASDAQ: BNTC | ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Benitec has tried to identify such forward-looking statements by use of such words as "expects,"
Slide 3: Executive Team
EXECUTIVE TEAM Jerel A. Banks, M.D., Ph.D. Megan Boston Gregory R. Reyes, Executive Director MD, Ph.D. Chief Executive Officer and Executive Chairman Head of Operations Australia Senior Scientific Advisor • CEO and Managing Director of • Former Chief Investment Officer of ASX listed entities • Forme
Slide 4: Corporate Snapshot
CORPORATE SNAPSHOT eos Meni ais Baines erent Listed NASDAQ Poe BNTC/BNTCW Share Price as of 30" September, 2018: (ADS ratio 20:1) A$0.18 US$2.37 52 week high/low as of 30 September, 2018 A$0.33/A$0.11 US$4.90 / US$1.85 (ADS) Average daily volume (6 months to 30" September, 2018) 448,251 shares 49,87
Slide 5: Value Drivers
Strong In-House Capabilities • Leadership and scientific teams possess extensive research & development and commercial expertise • In-house manufacturing expertise at every stage including preclinical, clinical, and commercial Unique & Proven Technology • Flexibility of ddRNAi platform can potential
Slide 6: FY 2018 Highlights
Corporate Restructuring • Restructured senior management and continued streamlining of operations to better position for value creation through scientific discovery and clinical advancement Secured Non-Dilutive Funding • Axovant Partnership - upfront and near-term cash payments totalling US$27.5M •
Slide 7: Key Highlight: Benitec-Axovant Agreement
KEY HIGHLIGHT: BENITEC-AXOVANT AGREEMENT Five Additional Secured Non-Diluted Funding Retain 30% Profits Fully-Funded Programs • Partner with Axovant on the • Upfront and near-term cash • Retain 30% of the net profits development of five payments totalling US$27.5M on worldwide sales of AXO- addition
Slide 8: First Benitec-Axovant Program C9orf72
FIRST BENITEC-AXOVANT PROGRAM C9orf72 AXO-AAV-ALS AXO-AAV-FTD • Preclinical • Preclinical • Identified a relationship • Mutations in the C9orf72 gene between C9orf72 mutations have been causally linked to and ALS FTD • Impacts ~40% of familial ALS • Approximately 40% of familial cases and ~8-10% of
Slide 9: Program Selection Insights C9orf72
PROGRAM SELECTION INSIGHTS Significant Unmet Medical Need Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal neurodegenerative disorders for which no effective treatments are available C9orf72 Genetic Abnormality Amenable to Treatment The characteristic hexanucleotide re
Slide 10: Corporate Strategy
Bolster the Core Management Team Planned additions to senior management and scientific teams will focus on gene therapy, drug development and industry leadership experience Build a Robust Pipeline Selectively develop proprietary and partnered pipeline programs for which our genetic medicines have a
Slide 11: Key New Hires
KEY NEW HIRES Associate Scientist / Lab Manager • Master’s degree in Molecular Biology and Microbiology from San Jose State University • Previously served as an Associate Scientist for Aridis Pharmaceuticals and Tacere Therapeutics Gregory R. Reyes, Ph.D. Scientist I Senior Scientific Advisor • PhD
Slide 12: Programs Pipeline
PROGRAMS PIPELINE Early Stage Late Stage R&D and Commercial Program Delivery Discovery Preclinical IND-Enabling Clinical (IND Clinical Budgeting Rights – Ph 2) (Ph 2 – Ph 3) Proprietary Programs Oncology – Head and Neck Squamous Cell Carcinoma (HNSCC) HNSCC Plasmid Global BB-401 Intratumoral HNSCC d
Slide 13: BB-401-01: Phase 2 Clinical Study in HNSCC
BB-401-01: PHASE 2 CLINICAL STUDY IN HNSCC Intratumoral BB-401 in patients with recurrent or metastatic head and neck squamous cell carcinoma Multi Center Single Arm Study Endpoints after 2 cycles of BB-401 Key Entry Criteria Fleming 2 Stage Design (1 cycle = 4 weekly injections BB-401) • Histologic
Slide 14: Head & Neck Squamous Cell Carcinoma
HEAD & NECK SQUAMOUS CELL CARCINOMA Clinical Candidate BB-401: Product Progress Status of Recruitment Number of Patients Enrolled Timeline of Interim Stage I recruitment Analysis is complete 14 patients are now enrolled Interim analysis expected be advised by Q1 of 2019
Slide 15: 2019 Milestones
Additional Proprietary Programs • Benitec to announce new proprietary pipeline program in Q1 2019 Axovant License and Collaboration Agreement 2019 • Benitec to become eligible for additional near-term MILESTONES cash payments totaling US$17.5 million Clinical Progress for BB-401 • Benitec to provide
Slide 16: Summary
Corporate restructuring better positions the company to create value through scientific discovery and clinical advancement Non-dilutive funding ensures that programs in the pipeline are fully-funded SUMMARY Licensing agreement with Axovant continues to produce a sustainable, positive impact in FY18
Slide 17: Contact: info@benitec.com
CONTACT: info@benitec.com NASDAQ: BNTC | ASX: BLT
Benitec Biopharma — Shareholder Meeting (November 2018) on 6ix